At the 2019 AAD meeting, 5-year follow-up data from the extension cohort of the phase 3 core trials ERASURE/FIXTURE was presented that showed that the IL-17A blocker secukinumab maintains long-term high levels of efficacy[1, 2]. Patients from the ERASURE/FIXTURE trials...
